Astellas Pharma Ltd.
Astellas Pharma Ltd., a leading global pharmaceutical company headquartered in the United Kingdom, is renowned for its innovative approach to healthcare. Founded in 2005 through the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd., Astellas has established a strong presence in key operational regions, including Europe, North America, and Asia. Specialising in areas such as urology, oncology, and immunology, Astellas is committed to developing unique therapies that address unmet medical needs. The company’s core products, including the prostate cancer treatment Xtandi and the antifungal agent Cresemba, exemplify its dedication to advancing patient care. With a robust pipeline and a focus on research and development, Astellas Pharma Ltd. continues to solidify its position as a prominent player in the global pharmaceutical industry, recognised for its contributions to innovative healthcare solutions.
DitchCarbon Score
How does Astellas Pharma Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Astellas Pharma Ltd.'s score of 32 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Astellas Pharma Ltd.'s reported carbon emissions
Astellas Pharma Ltd., headquartered in Great Britain, currently does not have publicly available carbon emissions data or specific reduction targets outlined. Without emissions figures, it is challenging to assess their current carbon footprint or the scope of their emissions (Scope 1, 2, or 3). However, the company is likely engaged in various climate commitments typical of the pharmaceutical industry, focusing on sustainability and reducing environmental impact. As the industry increasingly prioritises climate action, Astellas Pharma may be exploring initiatives to enhance energy efficiency, reduce waste, and transition to renewable energy sources. For a comprehensive understanding of Astellas Pharma's climate commitments and initiatives, further information would be required.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Astellas Pharma Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
